

House
Study
Bill
164
-
Introduced


HOUSE
FILE
_____


BY
(PROPOSED
COMMITTEE
ON


PUBLIC
SAFETY
BILL
BY


CHAIRPERSON
BAUDLER)


A
BILL
FOR


An
Act
relating
to
the
medical
use
of
cannabidiol
including
1


the
rescheduling
of
a
cannabidiol
investigational
product
2


approved
as
a
prescription
drug
medication
under
federal
law
3


and
including
effective
date
provisions.
4


BE
IT
ENACTED
BY
THE
GENERAL
ASSEMBLY
OF
THE
STATE
OF
IOWA:
5


TLSB
2301YC
(2)
87


rh/rj



H.F.
_____


Section
1.
Section
124.201,
Code
2017,
is
amended
by
adding
1


the
following
new
subsection:
2


NEW
SUBSECTION


.
5.
a.
If
a
cannabidiol
investigational
3


product
approved
as
a
prescription
drug
medication
by
the
4


United
States
food
and
drug
administration
is
designated
5


as
a
schedule
II
controlled
substance
by
the
federal
drug
6


enforcement
agency,
the
board
shall,
upon
notice
of
the
7


designation,
similarly
designate
the
prescription
drug
8


medication
as
a
schedule
II
controlled
substance
under
this
9


chapter.
Such
designation
by
the
board
shall
be
immediately
10


effective
upon
the
date
of
publication
in
the
federal
register
11


of
the
final
order
designating
the
prescription
drug
medication
12


as
a
schedule
II
controlled
substance.
13


b.
The
board
shall
adopt
rules
pursuant
to
chapter
17A
to
14


administer
this
subsection.
The
board
may
adopt
rules
on
an
15


emergency
basis
as
provided
in
section
17A.4,
subsection
3,
and
16


section
17A.5,
subsection
2,
to
administer
this
subsection,
17


and
the
rules
shall
be
effective
immediately
upon
filing
18


unless
a
later
date
is
specified
in
the
rules.
Any
emergency
19


rules
adopted
in
accordance
with
this
subsection
shall
also
be
20


published
as
a
notice
of
intended
action
as
provided
in
section
21


17A.4,
subsection
1.
22


Sec.
2.
REPEAL.
Section
124D.8,
Code
2017,
is
repealed.
23


Sec.
3.
EFFECTIVE
DATE.
The
section
of
this
Act
repealing
24


section
124D.8,
Code
2017,
takes
effect
June
30,
2017.
25


EXPLANATION
26


The
inclusion
of
this
explanation
does
not
constitute
agreement
with
27


the
explanationâ€™s
substance
by
the
members
of
the
general
assembly.
28


This
bill
relates
to
the
medical
use
of
cannabidiol,
29


including
the
rescheduling
of
a
cannabidiol
investigational
30


product
approved
as
a
prescription
drug
medication
under
31


federal
law.
32


The
bill
provides
if
a
cannabidiol
investigational
product
33


approved
as
a
prescription
drug
medication
by
the
United
States
34


food
and
drug
administration
is
designated
as
a
schedule
II
35


-1-


LSB
2301YC
(2)
87


rh/rj


1/
2




H.F.
_____


controlled
substance
by
the
federal
drug
enforcement
agency,
1


the
board
of
pharmacy
shall,
upon
notice
of
the
designation,
2


similarly
designate
the
prescription
drug
medication
as
3


a
schedule
II
controlled
substance.
Such
designation
by
4


the
board
shall
be
immediately
effective
upon
the
date
5


of
publication
in
the
federal
register
of
the
final
order
6


designating
the
prescription
drug
medication
as
a
schedule
II
7


controlled
substance.
8


The
bill
provides
that
the
board
shall
adopt
rules
pursuant
9


to
Code
chapter
17A
to
administer
the
bill
and
may
adopt
10


emergency
rules
which
shall
be
effective
immediately
upon
11


filing
unless
a
later
date
is
specified
in
the
rules.
Any
12


emergency
rules
adopted
shall
also
be
published
as
a
notice
of
13


intended
action
as
provided
in
Code
section
17A.4,
subsection
14


1.
15


The
bill
strikes
the
repeal
of
Code
chapter
124D
(medical
16


cannabidiol
Act)
before
the
repeal
becomes
effective
July
1,
17


2017.
18


-2-


LSB
2301YC
(2)
87


rh/rj


2/
2

